Daily Roundup | Tecentriq Approved After dMMR Colon Cancer Surgery & Zenbexus Topline: Median PFS 42 vs 20 Months

Thursday, October 8 edition, published after midnight Pacific.FDA approves Roche's Tecentriq (atezolizumab) with chemotherapy after stage III dMMR colon cancer surgery: fewer recurrence-or-death events, more frequent grade 3–4 adverse events. Bristol Myers Squibb reports a topline median progression-free survival of 42 vs 20 months for Zenbexus (iberdomide) in multiple myeloma; the result is not peer-reviewed, reports no overall survival result, and whether it verifies clinical benefit is the FDA's call. argenx stops its Phase 3 UNITY study of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in Sjögren's disease and says FB102 met its Phase 2 celiac primary endpoint. Plus Viatris's pending $1.65 billion Pacira deal (EXPAREL, ZILRETTA), PhRMA's GLOBE lawsuit, GenSight's GS030 retinitis pigmentosa study and Valneva's UK IXCHIQ revocation.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.